
    
      HZT-501, a fixed-dose combination of ibuprofen, a pain and inflammation relieving
      non-steroidal anti-inflammatory drug (NSAID), and famotidine, a histamine type 2 receptor
      antagonist (H2RA), is being developed for the treatment of patients with signs and symptoms
      of osteoarthritis, rheumatoid arthritis, mild to moderate pain or dysmenorrhea who are at
      risk of developing ibuprofen-associated upper gastrointestinal ulcers.
    
  